Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
- Conditions
- Advanced Cancer
- Interventions
- Drug: TQB2102 injection
- Registration Number
- NCT05735496
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Brief Summary
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB102 injection in subjects with advanced malignancies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 71
- Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study;
- Male or female patient 18 to 75 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and life expectancy ≥12 weeks;
- Histologically or cytologically confirmed, locally advanced tumors, Priority will be given to subjects with HER2 positive solid tumor;
- Malignant tumor that failed from standard treatment or had no standard treatment;
- According to the RECIST 1.1 standard, patient with at least one evaluable lesion;
- The main organs function well;
- Male or female patient had no plans to become pregnant and voluntarily took effective contraceptive measures from agree with the study to at least 6 months after the last dose of study drug.
- Concurrent secondary malignancy or other malignancy with no evidence of disease for more than 3 years;
- History of uncontrolled intercurrent illness;
- Major surgical procedure, radiotherapy, chemotherapy, or immunotherapy within 4 weeks prior to first dose;
- Patients with known symptomatic brain metastases;
- Receiving any other investigational agent within 4 weeks before first dose;
- Patients with severe hypersensitivity after the use of monoclonal antibodies
- History of interstitial lung disease or pneumonia;
- Unstable or serious concurrent medical conditions, as assessed by the Investigators, that would substantially increase the risk-benefit ratio of participating in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description TQB2102 injection TQB2102 injection intravenous infuse TQB2102 injection every three weeks, 21 days as a treatment cycle. (1.5mg/kg, 3mg/kg, 4.5mg/kg, 6mg/kg, 7.5mg/kg, 9mg/kg)
- Primary Outcome Measures
Name Time Method Maximum tolerated dose (MTD) During the first treatment cycle (21 days). MTD was defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients.
Dose Limiting Toxicity (DLT) During the first treatment cycle (21 days). DLT was defined as toxicities that meet pre-defined severity criteria (according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) toxicity assessment criteria), and assessed as having a suspected relationship to study drug that occurred within the first cycle (21 days) of treatment.
The occurrence rate of all adverse events (AEs) From date of the first dose until 28 days after last dose or new anti-tumor treatment, whichever came first. The occurrence of adverse events defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0)
The severity of all adverse events (AEs) From date of the first dose until 28 days after last dose or new anti-tumor treatment, whichever came first. The severity of adverse events defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0)
- Secondary Outcome Measures
Name Time Method Disease control rate (DCR) Baseline up to 2 years. Defined as the proportion of subjects with CR, PR, or SD (Stable Disease).
Progression-free survival (PFS) Baseline to the date of documented disease progression, up to 2 years. Defined as the time from first documented response to documented disease progression.
Immunogenicity Before infusion on Cycle1 Day1, Cycle2 Day1, Cycle 4 Day1, Cycle7 Day1, Cycle12 Day1 (each cycle is 21 days). 90 days after the end of the last infusion. Incidence of anti-drug antibody (ADA)
Peak concentration (Cmax) Before infusion, 15 minutes after infusion on Cycle1 Day1, Cycle2 Day1, Cycle3 Day1, Cycle4 Day1 and Cycle6 Day1; 4 hours, 7 hours, 7days and 14days after infusion on Cycle1 Day1; 4 hours and 7 hours after infusion on Cycle3 Day1. each cycle is 21 days Maximum observed concentration (Cmax) of ADC drug, total antibody, and small molecule toxin.
Terminal half-life (T1/2) Before infusion, 15 minutes after infusion on Cycle1 Day1, Cycle2 Day1, Cycle3 Day1, Cycle4 Day1 and Cycle6 Day1; 4 hours, 7 hours, 7days and 14days after infusion on Cycle1 Day1; 4 hours and 7 hours after infusion on Cycle3 Day1. each cycle is 21 day Terminal plasma half-life is the time required to divide the plasma concentration by two.
Area under the curve (AUC) Before infusion, 15 minutes after infusion on Cycle1 Day1, Cycle2 Day1, Cycle3 Day1, Cycle4 Day1 and Cycle6 Day1; 4hours, 7 hours, 7days and 14days after infusion on Cycle1 Day1; 4 hours and 7 hours after infusion on Cycle3 Day1. each cycle is 21 days The area under the curve (AUC) of serum or plasma concentration of ADC drug, total antibody, and small molecule toxin.
Duration of Response (DOR) Baseline to the date of documented disease progression, up to 2 years. Defined as the time from first documented response to documented disease progression.
Overall survival(OS) Baseline to the date of death from any cause, up to 2 years. Overall survival refers to the time from the first treatment to death from any cause.
Objective Response Rate (ORR) Baseline up to 2 years. Defined as the percentage of Complete Response (CR) plus partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria
Trial Locations
- Locations (1)
Sun Yat-sen University Cancer Center
🇨🇳Guangzhou, Guangdong, China